Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D277/24—Radicals substituted by oxygen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4245—Oxadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/426—1,3-Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/69—Boron compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
  • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
  • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
  • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
  • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
  • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
  • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
  • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
  • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
  • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
  • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
  • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
  • C07F5/02—Boron compounds
  • C07F5/025—Boronic and borinic acid compounds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
  • C07F5/02—Boron compounds
  • C07F5/027—Organoboranes and organoborohydrides

Definitions

• PD-1 Programmed cell death protein 1
• MHC major histocompatibility complex
• Activated T cells produce cytokines, such as Interferon- ⁇ , which in turn cause tumor cells to express programmed death ligand 1 (PD-L1) on the their cell surface.
• cytokines such as Interferon- ⁇
• PD-L1 programmed death ligand 1
• Tumors escape the action of immune system by utilizing the interaction between PD-1 and ligand PD-L1 resulting in lower effector T-cell function and survival, as such resulting in a suppressive immune response in the tumor microenvironment.
• the inhibition of the PD-1/PD-L1 interaction can enhance anti-tumor immunity and a large amount of work has been done to develop monoclonal antibodies as inhibitors of PD-1/PD-L1 interaction inhibitors.
• Pembrolizumab and cemiplimab, and nivolumab are three FDA approved anti-PD-1 antibodies.
• the discovery of small-molecule inhibitors would be an advantageous over antibodies, such as being fast-acting, simple for in vivo administration, ability to penetrate through cell membranes and interact with the cytoplasmic domains of cell surface receptors.
• 5 Since a few years, there has been significant development in designing PD-1/PD-L1 inhibitors. 6,7 Specifically, Bristol-Myers Squibb (BMS) discovered a set of potent PD-1/PD-L1 small molecule inhibitors based on the peptidomimetic molecules and non-peptidic small molecules.
• BMS revealed a 2-methyl-3-biphenyl- methanol scaffold containing chemical libraries.
• Holak et al. studied the interaction of BMS molecules with PD-L1 suggesting that BMS molecules induce PD-L1 dimerization and also reported crystal structures of compounds with dimeric PD-L1.
• ML machine learning
• the EGNN model takes advantage of a combination of local (A) and global (B) features.
• the local features are calculated from the molecular graph of a molecule using a GNN to assign weights to various sub-graphs of the molecule.
• the global features are a collection of docking scores used to represent the interactions between the compound and protein.
• Fig.2A Upper: Classification of Training Data in BMS and Incyte Patents; Bottom Left: Main PD-L1 inhibitor scaffolds of BMS patents. R group can be CN, Cl, Br, or CH 3 ; and Bottom Right: Main PD-L1 inhibitor scaffolds of Incyte patents.
• a and B denote sub-scaffolds.
• Figs.2B and 2C show heatmaps of pairwise Tanimoto similarity scores of BMS and Incyte compounds respectively.
• Figs.3A-3C The light pink chain represents the PD-1 protein and the pale cyan chain represents the PD-L1 protein in the PD-1/PD-L1 complex crystal structure (PDB ID: 4ZQK).
• the wheat color chain represents the PD-L1 chain A and the blue white color represents the PD-L1 chain B in the PD-L1 homodimer crystal structure (PDB ID: 5N2F)
• Fig.3A Overlapped and aligned PD-1/PD-L1 (4ZQK) and PD-L1 dimer (5N2F) crystal structures.
• FIG.3B Overlapped and aligned two crystal structures with the determined binding site (grey color mesh) of the PD-L1 dimer (5N2F).
• FIG.3C The PD-L1 dimer (5N2F) crystal structure with the small molecule (ligand ID: 8HW) at its binding site (grey color mesh).
• Fig.4A shows training-validation and Test scheme used for models
• Fig.4B depicts Cohen’s kappa scores for EGNN and GNN with different training- validation and test sets
• Fig.4C shows F1 scores for EGNN and GNN models with different training-validation and test sets
• Fig.4D shows Heatmap of pairwise Tanimoto similarity scores between BMS and Incyte compounds precision-recall curves for EGNN, GNN, RF and SVM models trained with Incyte data.
• Fig.5A shows that EGNN predicted a new PD-1/PD-L1 inhibitor, compound 4b, by scaffold hopping of BMS compounds, 4a or BMS-1 and BMS-1002. Blue colored parts of the 4b are added from the BMS-1002 and pink color part was added from the 4a (BMS-1).
• Fig.5B shows location of top docked pose of the compound 4b in PD-L1 homodimer crystal structure (PDB ID: 5N2F). Inset showing hydrophobic tunnel for compound 4b.
• Fig.5C shows chemical interactions of top docked pose interactions of the compound 4b in PD-L1 homodimer. Blue and pink colored parts are shown as sticks for 4b.
• Fig.5D shows comparison of IC 50 values of 4a (BMS-1 control compound, red color) and new compound 4b (blue color).
• the DMSO controls for positive (PC-DMSO, purple color) and negative controls (NC-DMSO, green color) of the assay are shown for each tested concentration.
• the term “substantially” can allow for a degree of variability in a value or range, for example, within 90%, within 95%, or within 99% of a stated value or of a stated limit of a range.
• the terms “a,” “an,” or “the” are used to include one or more than one unless the context clearly dictates otherwise.
• the term “or” is used to refer to a nonexclusive “or” unless otherwise indicated.
• the phraseology or terminology employed herein, and not otherwise defined is for the purpose of description only and not of limitation. Any use of section headings is intended to aid reading of the document and is not to be interpreted as limiting.
• alkyl refers to a saturated monovalent chain of carbon atoms, which may be optionally branched. It is understood that in embodiments that include alkyl, illustrative variations of those embodiments include lower alkyl, such as C 1 -C 6 alkyl, methyl, ethyl, propyl, 3-methylpentyl, and the like.
• alkenyl refers to an unsaturated monovalent chain of carbon atoms including at least one double bond, which may be optionally branched.
• alkenyl illustrative variations of those embodiments include lower alkenyl, such as C 2 -C 6 , C 2 -C 4 alkenyl, and the like.
• alkynyl refers to an unsaturated monovalent chain of carbon atoms including at least one triple bond, which may be optionally branched. It is understood that in embodiments that include alkynyl, illustrative variations of those embodiments include lower alkynyl, such as C 2 -C 6 , C 2 -C 4 alkynyl, and the like.
• cycloalkyl refers to a monovalent chain of carbon atoms, a portion of which forms a ring. It is understood that in embodiments that include cycloalkyl, illustrative variations of those embodiments include lower cylcoalkyl, such as C 3 -C 8 cycloalkyl, cyclopropyl, cyclohexyl, 3-ethylcyclopentyl, and the like.
• cycloalkenyl refers to an unsaturated monovalent chain of carbon atoms, a portion of which forms a ring.
• alkylene refers to a saturated bivalent chain of carbon atoms, which may be optionally branched. It is understood that in embodiments that include alkylene, illustrative variations of those embodiments include lower alkylene, such as C 2 -C 4 , alkylene, methylene, ethylene, propylene, 3-methylpentylene, and the like.
• each of alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkylene, and heterocycle may be optionally substituted with independently selected groups such as alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, carboxylic acid and derivatives thereof, including esters, amides, and nitrites, hydroxy, alkoxy, acyloxy, amino, alky and dialkylamino, acylamino, thio, and the like, and combinations thereof.
• heterocyclic or “heterocycle” refers to a monovalent chain of carbon and heteroatoms, wherein the heteroatoms are selected from nitrogen, oxygen, and sulfur, and a portion of which, at least one heteroatom, forms a ring.
• heterocycle may include both “aromatic heterocycles” and “non-aromatic heterocycles.”
• Heterocycles include 4-7 membered monocyclic and 8-12 membered bicyclic rings, such as imidazolyl, thiazolyl, oxazolyl, oxazinyl, thiazinyl, dithianyl, dioxanyl, isoxazolyl, isothiazolyl, triazolyl, furanyl, tetrahydrofuranyl, dihydrofuranyl, pyranyl, tetrazolyl, pyrazolyl, pyrazinyl, pyridazinyl, imidazolyl, pyridinyl, pyrrolyl, dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrimidinyl, morpholinyl, tetrahydrothiophenyl, thiopheny
• Heterocycles may be optionally substituted at any one or more positions capable of bearing a hydrogen atom.
• aryl includes monocyclic and polycyclic aromatic carbocyclic groups, each of which may be optionally substituted.
• optionally substituted aryl refers to an aromatic mono or polycyclic ring of carbon atoms, such as phenyl, naphthyl, and the like, which may be optionally substituted with one or more independently selected substituents, such as halo, hydroxyl, amino, alkyl, or alkoxy, alkylsulfony, cyano, nitro, and the like.
• heteroaryl or "aromatic heterocycle” includes substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6- membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
• heteroaryl may also include ring systems having one or two rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aromatic carbocycle, heteroaryl, and/or heterocycle.
• Heteroaryl groups include, without limitation, pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4- thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like.
• the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring- forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. [0033] In some embodiments, "heterocycloalkyl" refers to a non-aromatic heterocycle where one or more of the ring-forming atoms are a heteroatom such as an O, N, or S atom.
• Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems as well as spirocycles.
• Example heterocycloalkyl groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3- dihydrobenzofuryl, 1,3- benzodioxole, benzo-1,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like.
• heterocycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the nonaromatic heterocyclic ring, for example phthalimidyl, naphthalimidyl, and benzo derivatives of heterocycles.
• a heterocycloalkyl group having one or more fused aromatic rings can be attached though either the aromatic or non-aromatic portion.
• optionally substituted or “optional substituents,” as used herein, means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent, the substituents may be the same or different.
• the term “patient” includes human and non-human animals such as companion animals (dogs and cats and the like) and livestock animals. Livestock animals are animals raised for food production.
• the patient to be treated is preferably a mammal, in particular a human being.
• pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof.
• a pharmaceutically-acceptable material such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof.
• Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient.
• materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
• administering includes all means of introducing the compounds and compositions described herein to the patient, including, but are not limited to, oral (po), intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, inhalation, buccal, ocular, sublingual, vaginal, rectal, and the like.
• the compounds and compositions described herein may be administered in unit dosage forms and/or formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles.
• Solid medicinal forms can comprise inert components and carrier substances, such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginates, gelatine, guar gum, magnesium stearate, aluminium stearate, methyl cellulose, talc, highly dispersed silicic acids, silicone oil, higher molecular weight fatty acids, (such as stearic acid), gelatine, agar agar or vegetable or animal fats and oils, or solid high molecular weight polymers (such as polyethylene glycol); preparations which are suitable for oral administration can comprise additional flavorings and/or sweetening agents, if desired.
• carrier substances such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginates, gelatine, guar gum, magnesium stearate, aluminium stearate, methyl cellulose, talc, highly dispersed silicic acids, silicone oil, higher mole
• Liquid medicinal forms can be sterilized and/or, where appropriate, comprise auxiliary substances, such as preservatives, stabilizers, wetting agents, penetrating agents, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols for regulating the osmotic pressure or for buffering, and/or viscosity regulators.
• auxiliary substances such as preservatives, stabilizers, wetting agents, penetrating agents, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols for regulating the osmotic pressure or for buffering, and/or viscosity regulators.
• additives are tartrate and citrate buffers, ethanol and sequestering agents (such as ethylenediaminetetraacetic acid and its nontoxic salts).
• High molecular weight polymers such as liquid polyethylene oxides, microcrystalline celluloses, carboxymethyl celluloses, polyvinylpyrrolidones, dextrans or gelatine, are suitable for regulating the viscosity.
• solid carrier substances are starch, lactose, mannitol, methyl cellulose, talc, highly dispersed silicic acids, high molecular weight fatty acids (such as stearic acid), gelatine, agar, calcium phosphate, magnesium stearate, animal and vegetable fats, and solid high molecular weight polymers, such as polyethylene glycol.
• Oily suspensions for parenteral or topical applications can be vegetable, synthetic or semisynthetic oils, such as liquid fatty acid esters having in each case from 8 to 22 car bo n atoms in the fatty acid chains, for example palmitic acid, lauric acid, tridecanoic acid, margaric acid, stearic acid, arachidic acid, myristic acid, behenic acid, pentadecanoic acid, linoleic acid, elaidic acid, brasidic acid, erucic acid or oleic acid, which are esterified with monohydric to trihydric alcohols having from 1 to 6 carbon atoms, such as methanol, ethanol, propanol, butanol, pentanol or their isomers, glycol or glycerol.
• vegetable, synthetic or semisynthetic oils such as liquid fatty acid esters having in each case from 8 to 22 car bo n atoms in the fatty acid chains, for example palmitic acid
• fatty acid esters are commercially available miglyols, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG 6-capric acid, caprylic/capric acid esters of saturated fatty alcohols, polyoxyethylene glycerol trioleates, ethyl oleate, waxy fatty acid esters, such as artificial ducktail gland fat, coconut fatty acid isopropyl ester, oleyl oleate, decyl oleate, ethyl lactate, dibutyl phthalate, diisopropyl adipate, polyol fatty acid esters, inter alia.
• Silicone oils of differing viscosity are also suitable. It is furthermore possible to use vegetable oils, such as castor oil, almond oil, olive oil, sesame oil, cotton seed oil, groundnut oil, soybean oil or the like.
• Suitable solvents, gelatinizing agents and solubilizers are water or water miscible solvents.
• suitable substances are alcohols, such as ethanol or isopropyl alcohol, benzyl alcohol, 2-octyldodecanol, polyethylene glycols, phthalates, adipates, propylene glycol, glycerol, di- or tripropylene glycol, waxes, methyl cellosolve, cellosolve, esters, morpholines, dioxane, dimethyl sulphoxide, dimethylformamide, tetrahydrofuran, cyclohexanone, etc.
• alcohols such as ethanol or isopropyl alcohol
• benzyl alcohol 2-octyldodecanol
• polyethylene glycols phthalates, adipates
• propylene glycol glycerol
• di- or tripropylene glycol waxes
• methyl cellosolve cellosolve
• esters morpholines
• dioxane dimethyl sulphoxide
• dimethylformamide dimethylform
• ionic macromolecules such as sodium carboxymethyl cellulose, polyacrylic acid, polymethacrylic acid and their salts, sodium amylopectin semiglycolate, alginic acid or propylene glycol alginate as the sodium salt, gum arabic, xanthan gum, guar gum or carrageenan.
• glycerol paraffin of differing viscosity, triethanolamine, collagen, allantoin and novantisolic acid.
• surfactants for example of sodium lauryl sulphate, fatty alcohol ether sulphates, di-sodium-N-lauryl- iminodipropionate, polyethoxylated castor oil or sorbitan monooleate, sorbitan monostearate, polysorbates (e.g. Tween), cetyl alcohol, lecithin, glycerol monostearate, polyoxyethylene stearate, alkylphenol polyglycol ethers, cetyltrimethylammonium chloride or mono-/dialkylpolyglycol ether orthophosphoric acid monoethanolamine salts can also be required for the formulation.
• Stabilizers such as montmorillonites or colloidal silicic acids, for stabilizing emulsions or preventing the breakdown of active substances such as antioxidants, for example tocopherols or butylhydroxyanisole, or preservatives, such as p- hydroxybenzoic acid esters, can likewise be used for preparing the desired formulations.
• Preparations for parenteral administration can be present in separate dose unit forms, such as ampoules or vials. Use is preferably made of solutions of the active compound, preferably aqueous solution and, in particular, isotonic solutions and also suspensions.
• injection forms can be made available as ready-to-use preparations or only be prepared directly before use, by mixing the active compound, for example the lyophilisate, where appropriate containing other solid carrier substances, with the desired solvent or suspending agent.
• Intranasal preparations can be present as aqueous or oily solutions or as aqueous or oily suspensions. They can also be present as lyophilisates which are prepared before use using the suitable solvent or suspending agent.
• Inhalable preparations can present as powders, solutions or suspensions. Preferably, inhalable preparations are in the form of powders, e.g. as a mixture of the active ingredient with a suitable formulation aid such as lactose.
• a compound of the invention may be administered as a combination therapy with further active agents, e.g. therapeutically active compounds useful in the treatment of cancer, for example, prostate cancer, ovarian cancer, lung cancer, or breast cancer.
• the active ingredients may be formulated as compositions containing several active ingredients in a single dose form and/or as kits containing individual active ingredients in separate dose forms.
• the active ingredients used in combination therapy may be co-administered or administered separate.
• the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender, and diet of the patient: the time of administration, and rate of excretion of the specific compound employed, the duration of the treatment, the drugs used in combination or coincidentally with the specific compound employed; and like factors well known to the researcher, veterinarian, medical doctor or other clinician of ordinary skill. [0049] Depending upon the route of administration, a wide range of permissible dosages are contemplated herein, including doses falling in the range from about 1 ⁇ g/kg to about 1g/kg.
• the dosage may be single or divided, and may be administered according to a wide variety of dosing protocols, including q.d., b.i.d., t.i.d., or even every other day, once a week, once a month, and the like.
• the therapeutically effective amount described herein corresponds to the instance of administration, or alternatively to the total daily, weekly, or monthly dose.
• the term “therapeutically effective amount” refers to that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinicians, which includes alleviation of the symptoms of the disease or disorder being treated.
• the therapeutically effective amount is that which may treat or alleviate the disease or symptoms of the disease at a reasonable benefit/risk ratio applicable to any medical treatment.
• the term “therapeutically effective amount” refers to the amount to be administered to a patient, and may be based on body surface area, patient weight, and/or patient condition.
• test animals illustrated as described by Freireich, E. J., et al., Cancer Chemother. Rep.1966, 50 (4), 219, the disclosure of which is incorporated herein by reference.
• Body surface area may be approximately determined from patient height and weight (see, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, pages 537-538 (1970)).
• a therapeutically effective amount of the compounds described herein may be defined as any amount useful for inhibiting the growth of (or killing) a population of malignant cells or cancer cells, such as may be found in a patient in need of relief from such cancer or malignancy.
• such effective amounts range from about 5 mg/kg to about 500 mg/kg, from about 5 mg/kg to about 250 mg/kg, and/or from about 5 mg/kg to about 150 mg/kg of compound per patient body weight.
• the perm “patient” as used herein includes human beings and non-human animals such as companion animals (dogs, cats and the like) and livestock animals. Livestock animals are animals raised for food production.
• the patient to be treated is preferably a mammal, in particular a human being.
• the present invention generally relates to new compounds for therapeutic uses.
• this disclosure relates to novel compounds with immunomodulatory activities useful for treatment of various cancers.
• pharmaceutical compositions of such compounds and methods for treating a cancer patient by administering therapeutically effective amounts of such compound alone, together with other therapeutics, or in a pharmaceutical composition.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.
• the present invention relates to a compound having the formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar1 is an optionally substituted aryl or heteroaryl; R1 and R2 are, independently, hydrogen, a halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cyclo
• the present invention relates to a compound having the formula (I) as disclosed herein, wherein Ar1 is phenyl, 2,3-dihydrobenzo[b][1,4]-dioxine, or phenyl(thiazol-2-yl) methanol. [0059] In some illustrative embodiments, the present invention relates to a compound having the formula (I) as disclosed herein, wherein R 1 and R 2 are, independently, hydrogen, methyl, hydroxyl, methoxyl, or -OCH 2 Ar.
• the present invention relates to a compound having the formula (I) as disclosed herein, wherein R3 is CH3, CN, or Cl. [0061] In some illustrative embodiments, the present invention relates to a compound having the formula (I) as disclosed herein, wherein the compound comprises .
• the present invention relates to a compound having a formula (II): or a pharmaceutically acceptable salt thereof, wherein R1 is aryl, substituted aryl, heteroaryl; R 2 is a primary or secondary amine containing alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted; R3 is halo, azido, nitro, cyano, an alkyl
• the present invention relates to a compound having the formula (II) as disclosed herein, wherein Ar1 is phenyl, 2,3-dihydrobenzo[b][1,4]-dioxine, or phenyl(thiazol-2-yl) methanol.
• Ar1 is phenyl, 2,3-dihydrobenzo[b][1,4]-dioxine, or phenyl(thiazol-2-yl) methanol.
• the present invention relates to a compound having a formula (II) as disclosed herein, wherein R 3 is methyl, CN, or a halo.
• the present invention relates to a compound having a formula (II) as disclosed herein, wherein the compound is [0067]
• the present invention relates to a compound having a formula (III) as disclosed herein, wherein X is methyl, cyano, or chloro.
• the present invention relates to a compound having a formula (III) as disclosed herein, wherein the compound is .
• the present invention relates to a pharmaceutical composition comprising one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.
• the present invention relates to one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is an immune modulator.
• the present invention relates to one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is an inhibitor of PD-1 and PDL-1 signaling pathway.
• the present invention relates to one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is for the treatment of a cancer.
• the present invention relates to a method for treating a patient with a cancer, comprising the step of administering a therapeutically effective amount of one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients, to the patient in need of relief from said cancer.
• the present invention relates to a method for treating a patient with a cancer, comprising the step of administering a therapeutically effective amount of one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients, to the patient in need of relief from said cancer, wherein the compound is an immune modulator.
• the present invention relates to a method for treating a patient with a cancer, comprising the step of administering a therapeutically effective amount of one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, in combination with one or more other compounds of the same or different mode of action, and one or more carriers, diluents, or excipients, to the patient in need of relief from said cancer, wherein the compound is an immune modulator.
• the present invention relates to a method for treating a patient with a cancer, comprising the step of administering a therapeutically effective amount of one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients, to the patient in need of relief from said cancer, wherein said cancer is castration resistant prostate cancer.
• the present invention relates to a method for treating a patient with a cancer, comprising the step of administering a therapeutically effective amount of one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients, to the patient in need of relief from said cancer, wherein the compound is an immune modulator.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, for use as a medicament for cancer.
• the present invention relates to a drug conjugate comprising one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients.
• the present invention relates to a drug conjugate comprising one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients, wherein the conjugate confers cell-type or tissue type targeting or the conjugate targets another pathway that synergizes the action of those compounds.
• the present invention relates to a method for treating a cancer patient, comprising the step of administering a therapeutically effective amount of one or more compounds, together with one or more carriers, diluents, or excipients, to a patient in need of relief from said cancer, wherein the compound having the formula of (I), (II), or (III).
• the present invention relates to a compound having a formula (IV): pharmaceutically acceptable salt thereof, wherein represents a single or a double bond; represents an optional cyclic ring;
• R1 is hydrogen, a halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;
• R2 is hydrogen, a halo, azido
• the present invention relates to a compound having a formula (IV) as disclosed herein, wherein the compound is [0085]
• the present invention relates to a compound having a formula (V): pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , and R 3 , independently, represent five substituents selected from the group consisting of hydrogen, a halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, aryl
• the present invention relates to a compound having a formula (V) as disclosed herein, wherein the compounds are [0089]
• the present invention relates to a compound having formula VI or VII: or a pharmaceutically acceptable salt thereof, wherein A is a carbon or a nitrogen; L is (CH 2 ) n , -SO, -SO 2 , -CO, -CO(CH 2 )O, where n is 0, 1, 2;
• Ar1 is an aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;
• R 1 is halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroal
• the present invention relates to a compound having formula VIII: or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2; A is a carbon or a nitrogen; R 1 is halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted; and R2 is independently halo, -OR, -NO2, cyano,
• the present invention relates to a compound having formula IX: or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2; R1 is halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted; and R 2 is independently halo, -OR, -NO 2 , cyano, -NR a R
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.
• the present invention relates to a pharmaceutical composition comprising one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is an immune modulator.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is an inhibitor of PD-1 and PDL-1 signaling pathway.
• the present invention relates to a method for treating a cancer patient comprising the step of administering a therapeutically effective amount of one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is an inhibitor of PD-1 and PDL-1 signaling pathway.
• the present invention relates to a method for treating a cancer patient comprising the step of administering a therapeutically effective amount of one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, and one or more carriers, diluents, or excipients, to the cancer patient in need of relief from said cancer.
• the present invention relates to a method for treating a cancer patient comprising the step of administering a therapeutically effective amount of one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein in combination with one or more other compounds of the same or different mode of action, and one or more carriers, diluents, or excipients, to the cancer patient in need of relief from said cancer.
• the present invention relates to a method for treating a cancer patient comprising the step of administering a therapeutically effective amount of one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, and one or more carriers, diluents, or excipients, to the cancer patient in need of relief from said cancer, wherein the compound is an inhibitor of PD-1 and PDL-1 signaling pathway.
• the present invention relates to a method for treating a cancer patient comprising the step of administering a therapeutically effective amount of one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, and one or more carriers, diluents, or excipients, to the cancer patient in need of relief from said cancer, wherein said cancer is castration resistant prostate cancer.
• the present invention relates to a pharmaceutical composition comprising one or more compounds having the formulae of (I) ⁇ (IX) as disclosed herein, and one or more carriers, diluents, or excipients, for use as a medicament for cancer.
• the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 (PD-1/PD- L1) interaction is an immune checkpoint utilized by cancer cells to enhance immune suppression.
• PD-1/PD- L1 The Programmed Cell Death Protein 1/Programmed Death-Ligand 1
• synthesizing and validating large libraries of small-molecules to inhibit PD-1/PD-L1 interaction in a blind manner is both time-consuming and expensive.
• Our model incorporates two features: docking scores to represent the energy of binding (E) as a global feature and sub- graph features through a graph neural network (GNN) of molecular topology to represent local features.
• This Energy-Graph Neural Network (EGNN) model outperforms traditional machine learning methods as well as a simple GNN with a F1 score of 0.9524 and Cohen’s kappa score of 0.8861 for the hold out test set, suggesting that the topology of the small molecule, the structural interaction in the binding pocket, and chemical diversity of the training data are all important considerations for enhancing model performance.
• a Bootstrapped EGNN model was used to select compounds for synthesis and experimental validation with predicted high and low potency to inhibit PD-1/PD-L1 interaction.
• the potent inhibitor (4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2,6- dimethoxybenzyl)-D-serine, is a hybrid of two known bioactive scaffolds, and has an IC50 values of 339.9 nM that is comparatively better than the known bioactive compound.
• our bootstrapped EGNN model will be useful to identify target-specific high potency molecules designed by scaffold hopping, a well-known medicinal chemistry technique.
• ML architectures such as Support Vector Machine (SVM) 14–16 , Random Forest (RF) 17–19 , Graph Convolution Network 20 , and Graph Neural Networks (GNN) 21,22 have been used for drug design and predicting drug-target interactions 23,24 .
• SVM Support Vector Machine
• RF Random Forest
• GNN Graph Neural Networks
• new architectures utilizing a combination of graph features in the binding site of a protein have shown great promise for calculating binding affinities and determining whether a compound will bind to a target. 20,22
• Several new neural network-based architectures have also been proposed which promise to identify potent scaffolds, but many have not been tested experimentally, 15,16,25–28 and developments in the ability to mine and characterize protein crystallography data hopes to drive the creation of these models.
• the three-dimensional atomic interaction energetic scores are calculated using CANDOCK 31 (Fig.1B) and are combined with local molecular graph features (Fig.1A) using an end-to-end training methodology (Fig.1C-D).
• Fig.1B we use this EGNN model to select designs for synthesis, and experimentally test a curated list of compounds from these predictions to prospectively identify potent PD-L1 small molecule inhibitors using the Homogenous Time-Resolved Fluorescence (HTRF) assay.
• HTRF Homogenous Time-Resolved Fluorescence
• Patent Data for Training the EGNN Model [00106]
• a homogeneous time-resolved fluorescence (HTRF) binding assay was used to show activity against PD-1/PD-L1 interaction in the patents.
• the patents did not list individual IC50 values for all compounds but provided a range of inhibition with the different molecules.
• FIG. 2A shows the distribution of low and high potency molecules and general scaffolds in the BMS and Incyte patents.
• the BMS patents have 372 high potency compounds and 302 low potency compounds while the Incyte patents have 47 high potency compounds and 41 low potency compounds respectively.
• the BMS patent scaffolds contains 417 derivatives of (2-methyl-3-biphenylyl)methanol and 257 derivatives of [3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol shown in Figure 2A (bottom - left) with R groups as CN, Cl, Br, and CH3.
• Incyte patent scaffolds have distinct sub-scaffolds, denoted as A and B in Figure 2A (bottom – right).
• X denotes for either N or C—R groups (R: Alkyl groups).
• a PD-L1 homodimer crystal structure (PDB ID: 5N2F) was selected for docking all the compounds in this manuscript.
• a PD-1/PD-L1 crystal structure (PDB ID: 4ZQK) was also used to check whether the binding site location of PD-L1 in the homodimer crystal structure (5N2F) overlapped and aligned with each other using the PyMol software package 40 (Fig.3A).
• Fig.3B the selected binding site of the PD-L1 homodimer on the overlapped and aligned crystal structures is shown to indicate that the formation of the homodimer of PD-L1 with small molecules blocks the PD-1/PD-L1 interaction.
• a known inhibitor of the PD-1/PD-L1 interaction (ligand ID: 8HW) 8 in the selected binding site (Fig.3C) suggests that the selected binding site corresponding to PD-L1 homodimers is relevant to develop PD-1/PD-L1 inhibitors. Therefore, the docking interactions of the PD-L1 homodimer will be relevant towards identifying PD-1/PD-L1 inhibitors. Also, direct docking with the PD-1/PD-L1 was not carried out since the binding site in between the PD-1 and the PD-L1 is filled with interacting amino acid residues from both proteins. Therefore, there is no space to dock a small compound with the PD-1/PD-L1 complex.
• CANDOCK 31 was used to generate docking conformations of small molecules with PD-L1 homodimer (see Experimental Section on Generation of Energy Features with Docking and Energy Vector (E) in EGNN for details). Before developing a machine learning method, we also assessed the ability of only using the docking scores for compounds in the training set for each of the 96 potential energy scoring functions 31 in CANDOCK to classify the high potency vs low potency molecules. Cohen’s Kappa scores were used to select the best scoring functions to differentiate between two classes. (Table S1). The scoring function, radial cumulative complete 15 (RCC15) acquired the highest Cohen’s kappa score of 0.41447.
• a model with kappa score between 0.21 - 0.40 is considered as a fair agreement model and if the kappa score is between 0.41 - 0.60, then the model is considered as a moderate agreement model.
• EGNN Model with Hyperparameter Optimization Outperforms GNN and Other Baseline Models [00112] A detailed description of the EGNN model including a combination of molecular GNN combined with docking is given in the Experimental Section.
• Figure 1 shows that the EGNN model is a combination of local features of the small molecule represented as a GNN (see Graph Neural Network for Molecular Graphs in EGNN) along with global features of protein-ligand interaction represented as docking scores (see section Generation of Energy Features with Docking and Energy Vector (E) in EGNN).
• the EGNN was trained with 88 small molecules with high and low potency for PD-1/PD-L1 inhibition extracted from two Incyte patents (see Patent Data for Training the EGNN Model). We calculated variation in the average F1 score (over five cross-validated folds) versus the number of epochs for different hyperparameters (Figure S2).
• the EGNN and GNN models were trained with different training sets to examine the effect of chemical diversity on model performance for classification of high and low potency molecules. Two datasets (BMS and Incyte) were used separately and in combination to train the EGNN model and determine the best dataset to predict PD-1/PD-L1 inhibitors.
• Figure 4A shows how data sets were split within the train-validation-test set scheme. Initial dataset was split into two sets with the 4:1 ratio based on the scaffold splitting or random shuffled splitting. Then the 80% dataset was used as the training and validation dataset while the 20% dataset was used as the hold out test set to evaluate model performances. [00115] Fig.4A shows average F1 scores (over five-fold cross-validation) for both models trained with BMS compounds, Incyte compounds, and the union of these sets. The average F1 scores of the EGNN and GNN models trained with Incyte data were 0.956 ( ⁇ 0.051) and 0.678 ( ⁇ 0.157), respectively (Fig.4A).
• Bootstrapping is an essential statistical technique that can be used to select confident molecules for synthesis and experimental validation based on agreements among multiple models.
• the bootstrapped EGNN model identified high and low potency small molecules as PD-1/PD-L1 inhibitors that were synthesized and then experimentally verified with HTRF binding assay (see Table 2 for summary). Specifically, we selected 4 molecules predicted to be high or low potent for PD-1/PD-L1 inhibition for testing based on bootstrapped EGNN SoftMax average scores and standard deviation (see EGNN SoftMax scores in Table 2).
• the predicted high potency molecule (compound 4b) is (4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2- methylbenzyl)oxy)-2,6-dimethoxybenzyl)-D-serine, a hybrid of two BMS molecules, 4a (BMS-1) and BMS-1002 containing (2-methyl-3-biphenylyl)methanol and [3-(2,3-dihydro- 1,4-benzodioxin-6-yl)-2-methylphenyl]methanol, respectively (Figure 5A) and suggests the ability of EGNN model to do scaffold hopping.
• Scheme 1 Representative Synthesis Scheme a a Reaction conditions: (i) BH3•THF complex (1.0 M in THF), Anhydrous THF, 0 °C to rt, 2 days; (ii) PPh 3 , DIAD, 0 °C to rt, 20 h, anhydrous THF; (iii) amine component, NaBH3CN, cat.
• the central methylbenzyl ring (magenta color in 4b in Fig.5A) in the structure is rotated by approximately 30 o to 2,3-Dihydro-1,4- benzodioxine ring and the methyl group of the methylbenzyl ring point towards chain B of the PD-L1 homodimer.
• This orientation results in hydrophobic interactions with Met115 of both chain A and B of the homodimer and with BAla121.
• the D-serine end of the 4b compound forms hydrogen bonds with AThr20 and AAla121 along with a plausible hydrogen bond formation between backbone NH of A Tyr123 and the oxygen in one of the two methoxy groups of the 4b molecule (Fig.5C).
• IC 50 values for predicted active and inactive compounds with EGNN SoftMax scores [00131] DISCUSSION AND CONCLUSION [00132] Cancer immunotherapy marks a major step in treating cancer and the development of PD-1/PD-L1 immune checkpoint inhibitors have been an important area of research for treatment of several tumors.
• PD-1 pembrolizumab, nivolumab, and cemiplimab
• PD-L1 atezolizumab, durvalumab, and avelumab
• EGNN outperforms traditional ML architectures, such as, RF, SVM that include both local and global features, as well as the GNN model that uses only local features of small molecular topology.
• ML architectures such as, RF, SVM
• GNN model that uses only local features of small molecular topology.
• topology of the small molecule, the structural interaction in the binding pocket, and chemical diversity of the training data are all important considerations for enhancing model performance.
• We used a bootstrapped EGNN model (based on 1000 EGNN models) for prediction and confident selection of new molecules for chemical synthesis and subsequent testing of inhibition using HTRF PD-1/PD-L1 inhibition assay.
• the predicted high potency molecule (4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2,6- dimethoxybenzyl)-D-serine, is a hybrid of two BMS high potency molecular scaffolds, and has an IC 50 value of 339.9 nM for inhibiting PD-1/PD-L1 interaction, suggesting the ability of EGNN model to do scaffold hopping to identify new inhibitors.
• EXPERIMENTAL SECTION [00137] Homogenous Time-Resolved Fluorescence (HTRF) Assay to Test Inhibition of Predicted Compounds [00138] Inhibition of PD-1/PD-L1 interaction was tested for 4 high and low potent predicted compounds using the PD1/PD-L1 HTRF assay kit from Cisbio US, Inc. The assay protocol was used as mentioned in the kit for each predicted compound (4b, 4c, 4d and 4e) and the BMS control compound (4a).
• HTRF Homogenous Time-Resolved Fluorescence
• the ⁇ R ratio indicating “specific signal” of the compound disrupting the PD-1/PD-L1 interaction was calculated by subtracting background HTRF ratio (negative DMSO control in our work) from each compound (sample) HTRF ratio as follows; [00141] Next, data normalization was done to minimize variation in values on different days, different plate reader instruments, or if the assay was done by different individuals. The normalization was done with respect to the background HTRF ratio and was calculated as follows; [00142] Finally, the ratio was calculated to enable comparison of values between multiple experiments. wherein is taken as the of the positive DMSO control in the assay.
• IC50 value for PD-1/PD-L1 inhibition was determined by analyzing the log of the concentration ⁇ response curves to fit a sigmoid curve with four-parameter logistic (4PL) regression using the GraphPad Prism Software version 8.3.0 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com.
• the HTRF_IC50_Data.xlsx data file with all replicates is provided as a Supporting File for use in GraphPad Prism Software to calculate IC 50 values.
• Machine Learning Architecture of the EGNN model [00146] The EGNN model was developed using PyTorch 47 . All scripts for implementing the machine learning model and results are provided on GitHub at https://github.com/chopralab/egnn. The Fig.1 shows the overview of the EGNN machine learning architecture. We implemented the Graph Neural Networks for the molecular graph by Tsubaki and coworkers. 24 . Briefly, the molecular structures were converted into SMILES strings using ChemAxon MolConverter 48 software.
• a graph can be defined as , here; L and M are sets of vertices and edges respectively.
• atoms When applied to chemistry, atoms can be defined as vertices and chemical bonds can be defined as edges.
• all the atoms and chemical bonds will be embedded as real valued vectors with d-dimensions based on their different types. Since the diversity of atoms (eg: C, N, O, etc.) and bonds (eg: single bonds, double bonds, triple bonds, etc.) in a small molecule is limited, the number of learning parameters are limited. Therefore, a strategy called r-radius sub-graphs 50 was used to avoid this limitation.
• r-radius Sub-graphs [ 00151] The set of all atoms within a defined ⁇ radius an atom ⁇ can be represented as W hen the , which is the set of all atoms in the molecule.
• the r-radius sub-graph of the ⁇ th vertex is defined as follows; wherein, The r-radius sub-graph for the edge between ⁇ th and Tth atoms was defined as follows; [00152] Randomly initialized embeddings (Fig.1) are assigned to each r-radius and vertex based on the type. Backpropagation has been used to train these random embeddings.
• Vertex Transition Function is the embedded vector for the th vertex of a given molecular graph F at time step ⁇ . Then the updated 4 vector can be written as follows; wherein, N ⁇ is denoting the set of neighboring atoms, Z is the sigmoid function which is defined as the hidden vector which defines the neighborhood and can be calculated as follows; wherein, b is the Rectified Linear Units (ReLU), a non-linear activation function such ⁇ are the weight matrix and the bias vector respectively.
• ReLU Rectified Linear Units
• edge transition function is used to update each embedded edge vector during the training process.
• d are the weight matrix and the bias vector respectively.
• d are added, because there is no direction for edges in molecular graphs.
• Molecular Vector Output of Molecular GNN [00158] The transition function generates an updated set of atom (vertex) vectors Then the output function uses this set of atom vectors to obtain an unique molecular vector K C+58tu58 (Fig.1A), which is defined as follows; wherein, the total number of vertices in the full molecular graph is denoted by the
• radial-mean- reduced-6 (RMR6) 31 was used as “Selector” parameters for docking to select the top pose 31 .
• the top pose of each docked compound was selected, and its docking score was recalculated using all the available 96 different potential energy functions in CANDOCK 31 software. All 96 CANDOCK docking energy scores of each molecule were normalized for each potential energy function to use as a vector in the EGNN model; wherein, is the number of potential energy scoring functions and ⁇ is the number of molecules in the dataset.
• ⁇ x 4,R is the normalized docking energy value for the energy score with ⁇ th potential energy function for the Tth docked molecule.
• ⁇ 4,R is the docking energy score before normalization.
• the EGNN model was trained with back propagation with given SMILES strings, the vectors of RCR15 and RCC15 scores generated by CANDOCK 31 and their high potency or low potency status with the PD-L1 protein.
• the trained model can be used to predict the probability of a given molecule to be a high or low potent molecule towards the PD-L1 protein.
• EGNN Training and Hyperparameter Optimization [00165] The model takes a SMILES string and a docking energy score string for a given molecule as inputs. Hyperparameters of the model were optimized before using it for predictions.
• the BMS compound 4a (BMS-1 or KPGC01S94) 7 as well as compounds 4b-c were synthesized according to the reported procedures starting from compound 1, 2a-b, 3a-b and spectral data were in accordance with reported data. 6–8 [00170]
• Step-1 2-(3-bromo-2-methylphenyl)-5-((4-fluorophenyl) (piperidin-1-yl)methyl)- 1,3,4-oxadiazole:
• a mixture of piperidine (1 equiv), 4-fluorobenzaldehyde (1 equiv), N-(isocyanoimino) triphenyl phosphorane (1 equiv) was dissolved in DCM (5 mL/mmol).
• the solution of 3-bromo-2- methyl-benzoic acid (1 equiv) in DCM was added slowly to the reaction mixture at room temperature and allowed to stir at 50-60 o C for 2 hours.
• Step-2 2-((4-fluorophenyl)(piperidin-1-yl)methyl)-5-(2-methyl-[1,1'-biphenyl]-3- yl)-1,3,4-oxadiazole (2a): In a clean dried screw cap vial with magnetic stir bar, a mixture of 2-(3-bromo-2-methylphenyl)-5-((4-fluorophenyl) (piperidin-1-yl)methyl)-1,3,4-oxadiazole (1 equiv), phenylboronic acid (2 equiv) and PdCl 2 (dppf) 2 -CH 2 Cl 2 (3 mol%) were taken and purged once with Argon.
• Step-1 3-Bromo-N,2-dimethylaniline (1 equiv), (2,3-dihydrobenzo[b][1,4]dioxin- 6-yl)boronic acid (1.5 equiv), PdCl2(dppf)•CH2Cl2 (3 mol%) in Toluene:Ethanol (1.5:0.5 mL) and purged twice with Argon.1M NaHCO3 (1.5 mL) was added under inert atmosphere and it was allowed to stir at 80 °C for 45 mins. The reaction was monitored by TLC.
• Step-2 A mixture of 3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-N,2- dimethylaniline (1 equiv), propionaldehyde (1.1 equiv), (N- Isocyanoimino)triphenylphosphorane in DCM was added benzoic acid (1.1 equiv) in portions. The reaction mixture was stirred at 40 °C for 2-3 hours. The reaction was monitored by TLC.
• Step-1 3-Bromo-N,2-dimethylaniline (1 equiv), phenylboronic acid (1.5 equiv), PdCl 2 (dppf)•CH 2 Cl 2 (3 mol%) in Toluene: Ethanol (1.5:0.5 mL) and purged twice with Argon.1M NaHCO3 (1.5 mL) was added under inert atmosphere and it was allowed to stir at 80 °C for 45 mins. The reaction was monitored by TLC.
• Step-2 A mixture of N,2-dimethyl-[1,1'-biphenyl]-3-amine (1 equiv), propionaldehyde (1.1 equiv), (N-Isocyanoimino)triphenylphosphorane in DCM was added benzoic acid (1.1 equiv) in portions. The reaction mixture was stirred at 40 °C for 2-3 hours. The reaction was monitored by TLC. The product was purified by flash column chromatography using 0-60% Hexane: Ethylacetate to get oily product (48% yield).
• Diabetes 2017, 66 (11), 2875–2887. (35) Ma, X.; Zhou, J.; Wang, C.; Carter-Cooper, B.; Yang, F.; Larocque, E.; Fine, J.; Tsuji, G.; Chopra, G.; Lapidus, R. G.; et al. Identification of New FLT3 Inhibitors Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach. ACS Med. Chem. Lett.2017, 8 (5). (36) Fine, J.; Lackner, R.; Samudrala, R.; Chopra, G. Computational Chemoproteomics to Understand the Role of Selected Psychoactives. Sci.
• PROC An Open-Source Package for R and S+ to Analyze and Compare ROC Curves.
• the present invention generally relates to compounds with immunomodulatory activity and their therapeutic uses. Also described herein are pharmaceutical compositions of such compounds and methods for treating a cancer patient by administering therapeutically effective amounts of such compound alone, together with other therapeutics, or in a pharmaceutical composition.
• PD-1 Programmed cell death protein 1
• MHC major histocompatibility complex
• Activated T cells produce cytokines, such as Interferon-g, which in turn cause tumor cells to express programmed death ligand 1 (PD-L1) on the their cell surface.
• Tumors escape the action of immune system by utilizing the interaction between PD-1 and ligand PD-L1 resulting in lower effector T-cell function and survival, as such resulting in a suppressive immune response in the tumor microenvironment.
• BMS Bristol-Myers Squibb
• Fig. 1 The EGNN model takes advantage of a combination of local (A) and global (B) features.
• the local features are calculated from the molecular graph of a molecule using a GNN to assign weights to various sub-graphs of the molecule.
• the global features are a collection of docking scores used to represent the interactions between the compound and protein. These two features are combined to create a concatenated vector (C) which is passed through a SoftMax layer and bootstrapped to classify a molecule as having ‘low’ or ‘high’ potency against PD-1/PD-L1 interaction.
• C concatenated vector
• FIG. 2A Upper: Classification of Training Data in BMS and Incyte Patents; Bottom Left: Main PD-L1 inhibitor scaffolds of BMS patents.
• R group can be CN, Cl, Br, or CH3; and Bottom Right: Main PD-L1 inhibitor scaffolds of Incyte patents.
• a and B denote sub- scaffolds.
• Figs. 2B and 2C show heatmaps of pairwise Tanimoto similarity scores of BMS and Incyte compounds respectively.
• Figs. 3A-3C The light pink chain represents the PD- 1 protein and the pale cyan chain represents the PD-L1 protein in the PD-1/PD-L1 complex crystal structure (PDB ID: 4ZQK).
• the wheat color chain represents the PD-L1 chain A and the blue white color represents the PD-L1 chain B in the PD-L1 homodimer crystal structure (PDB ID: 5N2F)
• FIG. 3A Overlapped and aligned PD-1/PD-L1 (4ZQK) and PD-L1 dimer (5N2F) crystal structures.
• FIG. 3B Overlapped and aligned two crystal structures with the determined binding site (grey color mesh) of the PD-L1 dimer (5N2F).
• FIG. 3C The PD-L1 dimer (5N2F) crystal structure with the small molecule (ligand ID: 8HW) at its binding site (grey color mesh).
• Fig. 4A shows training-validation and Test scheme used for models
• Fig. 4B depicts Cohen’s kappa scores for EGNN and GNN with different training- validation and test sets;
• Fig. 4C shows FI scores for EGNN and GNN models with different training-validation and test sets; and Fig. 4D shows Heatmap of pairwise Tanimoto similarity scores between BMS and Incyte compounds precision-recall curves for EGNN, GNN, RF and SVM models trained with Incyte data.
• Fig. 5A shows that EGNN predicted a new PD-1/PD-L1 inhibitor, compound 4b, by scaffold hopping of BMS compounds, 4a or BMS-1 and BMS-1002. Blue colored parts of the 4b are added from the BMS-1002 and pink color part was added from the 4a (BMS-1).
• Fig. 5B shows location of top docked pose of the compound 4b in PD-L1 homodimer crystal structure (PDB ID: 5N2F). Inset showing hydrophobic tunnel for compound 4b.
• Fig. 5C shows chemical interactions of top docked pose interactions of the compound 4b in PD-L1 homodimer. Blue and pink colored parts are shown as sticks for 4b. The dotted yellow lines between the compound and the residues A T1IT20 and A AM21 represent hydrogen bonding. The orientation of the aromatic ring of tyrosine, A Tyr56, suggests a plausible p- p interaction with 2,3-dihydro- 1,4-benzodioxin blue colored aromatic ring in the compound 4b.
• Fig. 5D shows comparison of IC50 values of 4a (BMS-1 control compound, red color) and new compound 4b (blue color).
• the DMSO controls for positive (PC-DMSO, purple color) and negative controls (NC-DMSO, green color) of the assay are shown for each tested concentration.
• the term “about” can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated limit of a range.
• the term “substantially” can allow for a degree of variability in a value or range, for example, within 90%, within 95%, or within 99% of a stated value or of a stated limit of a range.
• a "halogen” designates F, Cl, Bror I.
• a "halogen-substitution” or “halo” substitution designates replacement of one or more hydrogen atoms with F, Cl, Br or I.
• alkyl refers to a saturated monovalent chain of carbon atoms, which may be optionally branched. It is understood that in embodiments that include alkyl, illustrative variations of those embodiments include lower alkyl, such as C1-C6 alkyl, methyl, ethyl, propyl, 3-methylpentyl, and the like.
• alkenyl refers to an unsaturated monovalent chain of carbon atoms including at least one double bond, which may be optionally branched. It is understood that in embodiments that include alkenyl, illustrative variations of those embodiments include lower alkenyl, such as Ci-Ce , C 2 -C 4 alkenyl, and the like.
• alkynyl refers to an unsaturated monovalent chain of carbon atoms including at least one triple bond, which may be optionally branched. It is understood that in embodiments that include alkynyl, illustrative variations of those embodiments include lower alkynyl, such as Ci-Ce , C 2 -C 4 alkynyl, and the like.
• cycloalkyl refers to a monovalent chain of carbon atoms, a portion of which forms a ring. It is understood that in embodiments that include cycloalkyl, illustrative variations of those embodiments include lower cylcoalkyl, such as C 3 -C 8 cycloalkyl, cyclopropyl, cyclohexyl, 3-ethylcyclopentyl, and the like.
• cycloalkenyl refers to an unsaturated monovalent chain of carbon atoms, a portion of which forms a ring. It is understood that in emobodiments that include cycloalkenyl, illustrative variations of those embodiments include lower cycloalkenyl, such as C 3 -C 8 , C 3 -C 6 cycloalkenyl.
• alkylene refers to a saturated bivalent chain of carbon atoms, which may be optionally branched. It is understood that in embodiments that include alkylene, illustrative variations of those embodiments include lower alkylene, such as C2-C4, alkylene, methylene, ethylene, propylene, 3-methylpentylene, and the like.
• each of alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkylene, and heterocycle may be optionally substituted with independently selected groups such as alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, carboxylic acid and derivatives thereof, including esters, amides, and nitrites, hydroxy, alkoxy, acyloxy, amino, alky and dialkylamino, acylamino, thio, and the like, and combinations thereof.
• heterocyclic or “heterocycle” refers to a monovalent chain of carbon and heteroatoms, wherein the heteroatoms are selected from nitrogen, oxygen, and sulfur, and a portion of which, at least one heteroatom, forms a ring.
• heterocycle may include both “aromatic heterocycles” and “non-aromatic heterocycles.”
• Heterocycles include 4-7 membered monocyclic and 8-12 membered bicyclic rings, such as imidazolyl, thiazolyl, oxazolyl, oxazinyl, thiazinyl, dithianyl, dioxanyl, isoxazolyl, isothiazolyl, triazolyl, furanyl, tetrahydrofuranyl, dihydrofuranyl, pyranyl, tetrazolyl, pyrazolyl, pyrazinyl, pyridazinyl, imidazolyl, pyridinyl, pyrrolyl, dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrimidinyl, morpholinyl, tetrahydrothiophenyl, thiopheny
• aryl includes monocyclic and polycyclic aromatic carbocyclic groups, each of which may be optionally substituted.
• optionally substituted aryl refers to an aromatic mono or polycyclic ring of carbon atoms, such as phenyl, naphthyl, and the like, which may be optionally substituted with one or more independently selected substituents, such as halo, hydroxyl, amino, alkyl, or alkoxy, alkylsulfony, cyano, nitro, and the like.
• heteroaryl or "aromatic heterocycle” includes substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6- membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
• heteroaryl may also include ring systems having one or two rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aromatic carbocycle, heteroaryl, and/or heterocycle.
• Heteroaryl groups include, without limitation, pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4- thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like.
• the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring- forming atoms. In some embodiments, the heteroaryl group has l to about 4, lto about 3, or 1 to 2 heteroatoms.
• 'heterocycloalkyl refers to anon-aromatic heterocycle where one or more of the ring-forming atoms are a heteroatom such as an O, N, or S atom.
• Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems as well as spirocycles.
• Example heterocycloalkyl groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3- dihydrobenzofuryl, 1,3- benzodioxole, benzo-l,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like.
• heterocycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the nonaromatic heterocyclic ring, for example phthalimidyl, naphthalimidyl, and benzo derivatives of heterocycles.
• a heterocycloalkyl group having one or more fused aromatic rings can be attached though either the aromatic or non-aromatic portion.
• substituents means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent, the substituents may be the same or different. Furthermore, when using the terms “independently,” “independently are,” and “independently selected from” mean that the groups in question may be the same or different. Certain of the herein defined terms may occur more than once in the structure, and upon such occurrence each term shall be defined independently of the other.
• the term “patient” includes human and non-human animals such as companion animals (dogs and cats and the like) and livestock animals. Livestock animals are animals raised for food production.
• the patient to be treated is preferably a mammal, in particular a human being.
• pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof.
• a pharmaceutically-acceptable material such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof.
• Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient.
• materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
• administering includes all means of introducing the compounds and compositions described herein to the patient, including, but are not limited to, oral (po), intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, inhalation, buccal, ocular, sublingual, vaginal, rectal, and the like.
• the compounds and compositions described herein may be administered in unit dosage forms and/or formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles.
• Solid medicinal forms can comprise inert components and carrier substances, such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginates, gelatine, guar gum, magnesium stearate, aluminium stearate, methyl cellulose, talc, highly dispersed silicic acids, silicone oil, higher molecular weight fatty acids,
• carrier substances such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginates, gelatine, guar gum, magnesium stearate, aluminium stearate, methyl cellulose, talc, highly dispersed silicic acids, silicone oil, higher molecular weight fatty acids,
• preparations which are suitable for oral administration can comprise additional flavorings and/or sweetening agents, if desired.
• Liquid medicinal forms can be sterilized and/or, where appropriate, comprise auxiliary substances, such as preservatives, stabilizers, wetting agents, penetrating agents, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols for regulating the osmotic pressure or for buffering, and/or viscosity regulators.
• auxiliary substances such as preservatives, stabilizers, wetting agents, penetrating agents, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols for regulating the osmotic pressure or for buffering, and/or viscosity regulators.
• additives are tartrate and citrate buffers, ethanol and sequestering agents (such as ethylenediaminetetraacetic acid and its nontoxic salts).
• High molecular weight polymers such as liquid polyethylene oxides, microcrystalline celluloses, carboxymethyl celluloses, polyvinylpyrrolidones, dextrans or gelatine, are suitable for regulating the viscosity.
• solid carrier substances are starch, lactose, mannitol, methyl cellulose, talc, highly dispersed silicic acids, high molecular weight fatty acids (such as stearic acid), gelatine, agar, calcium phosphate, magnesium stearate, animal and vegetable fats, and solid high molecular weight polymers, such as polyethylene glycol.
• Oily suspensions for parenteral or topical applications can be vegetable, synthetic or semisynthetic oils, such as liquid fatty acid esters having in each case from 8 to 22 carbon atoms in the fatty acid chains, for example palmitic acid, lauric acid, tridecanoic acid, margaric acid, stearic acid, arachidic acid, myristic acid, behenic acid, pentadecanoic acid, linoleic acid, elaidic acid, brasidic acid, erucic acid or oleic acid, which are esterified with monohydric to trihydric alcohols having from 1 to 6 carbon atoms, such as methanol, ethanol, propanol, butanol, pentanol or their isomers, glycol or glycerol.
• vegetable, synthetic or semisynthetic oils such as liquid fatty acid esters having in each case from 8 to 22 carbon atoms in the fatty acid chains, for example palmitic acid, lauric acid,
• fatty acid esters are commercially available miglyols, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG 6-capric acid, caprylic/capric acid esters of saturated fatty alcohols, polyoxyethylene glycerol trioleates, ethyl oleate, waxy fatty acid esters, such as artificial ducktail gland fat, coconut fatty acid isopropyl ester, oleyl oleate, decyl oleate, ethyl lactate, dibutyl phthalate, diisopropyl adipate, polyol fatty acid esters, inter alia.
• Silicone oils of differing viscosity are also suitable. It is furthermore possible to use vegetable oils, such as castor oil, almond oil, olive oil, sesame oil, cotton seed oil, groundnut oil, soybean oil or the like.
• Suitable solvents, gelatinizing agents and solubilizers are water or water miscible solvents.
• suitable substances are alcohols, such as ethanol or isopropyl alcohol, benzyl alcohol, 2-octyldodecanol, polyethylene glycols, phthalates, adipates, propylene glycol, glycerol, di- or tripropylene glycol, waxes, methyl cellosolve, cellosolve, esters, morpholines, dioxane, dimethyl sulphoxide, dimethylformamide, tetrahydrofuran, cyclohexanone, etc.
• alcohols such as ethanol or isopropyl alcohol, benzyl alcohol, 2-octyldodecanol, polyethylene glycols, phthalates, adipates, propylene glycol, glycerol, di- or tripropylene glycol, waxes, methyl cellosolve, cellosolve, esters,
• gelatinizing agents and film-forming agents are also perfectly possible.
• ionic macromolecules such as sodium carboxymethyl cellulose, polyacrylic acid, polymethacrylic acid and their salts, sodium amylopectin semiglycolate, alginic acid or propylene glycol alginate as the sodium salt, gum arabic, xanthan gum, guar gum or carrageenan.
• surfactants for example of sodium lauryl sulphate, fatty alcohol ether sulphates, di-sodium-N-lauryl- iminodipropionate, polyethoxylated castor oil or sorbitan monooleate, sorbitan monostearate, polysorbates (e.g. Tween), cetyl alcohol, lecithin, glycerol monostearate, polyoxyethylene stearate, alkylphenol polyglycol ethers, cetyltrimethylammonium chloride or mono-/dialkylpolyglycol ether orthophosphoric acid monoethanolamine salts can also be required for the formulation.
• Stabilizers such as montmorillonites or colloidal silicic acids, for stabilizing emulsions or preventing the breakdown of active substances such as antioxidants, for example tocopherols or butylhydroxyanisole, or preservatives, such as p- hydroxybenzoic acid esters, can likewise be used for preparing the desired formulations.
• Preparations for parenteral administration can be present in separate dose unit forms, such as ampoules or vials. Use is preferably made of solutions of the active compound, preferably aqueous solution and, in particular, isotonic solutions and also suspensions. These injection forms can be made available as ready-to-use preparations or only be prepared directly before use, by mixing the active compound, for example the lyophilisate, where appropriate containing other solid carrier substances, with the desired solvent or suspending agent.
• Intranasal preparations can be present as aqueous or oily solutions or as aqueous or oily suspensions. They can also be present as lyophilisates which are prepared before use using the suitable solvent or suspending agent.
• inhalable preparations can present as powders, solutions or suspensions.
• inhalable preparations are in the form of powders, e.g. as a mixture of the active ingredient with a suitable formulation aid such as lactose.
• the preparations are produced, aliquoted and sealed under the customary antimicrobial and aseptic conditions.
• a compound of the invention may be administered as a combination therapy with further active agents, e.g. therapeutically active compounds useful in the treatment of cancer, for example, prostate cancer, ovarian cancer, lung cancer, or breast cancer.
• the active ingredients may be formulated as compositions containing several active ingredients in a single dose form and/or as kits containing individual active ingredients in separate dose forms.
• the active ingredients used in combination therapy may be co-administered or administered separate
• the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender, and diet of the patient: the time of administration, and rate of excretion of the specific compound employed, the duration of the treatment, the drugs used in combination or coincidentally with the specific compound employed; and like factors well known to the researcher, veterinarian, medical doctor or other clinician of ordinary skill.
• a wide range of permissible dosages are contemplated herein, including doses falling in the range from about lpg/kg to about lg/kg.
• the dosage may be single or divided, and may be administered according to a wide variety of dosing protocols, including q.d., b.i.d., t.i.d., or even every other day, once a week, once a month, and the like.
• the therapeutically effective amount described herein corresponds to the instance of administration, or alternatively to the total daily, weekly, or monthly dose.
• the term “therapeutically effective amount” refers to that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinicians, which includes alleviation of the symptoms of the disease or disorder being treated.
• the therapeutically effective amount is that which may treat or alleviate the disease or symptoms of the disease at a reasonable benefit/risk ratio applicable to any medical treatment.
• the term “therapeutically effective amount” refers to the amount to be administered to a patient, and may be based on body surface area, patient weight, and/or patient condition.
• body surface area may be approximately determined from patient height and weight (see, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, pages 537-538 (1970)).
• a therapeutically effective amount of the compounds described herein may be defined as any amount useful for inhibiting the growth of (or killing) a population of malignant cells or cancer cells, such as may be found in a patient in need of relief from such cancer or malignancy.
• effective amounts range from about 5 mg/kg to about 500 mg/kg, from about 5 mg/kg to about 250 mg/kg, and/or from about 5 mg/kg to about 150 mg/kg of compound per patient body weight. It is appreciated that effective doses may also vary depending on the route of administration, optional excipient usage, and the possibility of co-usage of the compound with other conventional and non-conventional therapeutic treatments, including other anti-tumor agents, radiation therapy, and the like.
• the perm “patient” as used herein includes human beings and non-human animals such as companion animals (dogs, cats and the like) and livestock animals. Livestock animals are animals raised for food production.
• the patient to be treated is preferably a mammal, in particular a human being.
• PD-1 programmed cell death- 1 PD-L1 programmed death-ligand-1
• GNN graph neural network EGNN energy graph neural network
• SVM support vector machines RF random forest
• FDA U.S. Food and Drug Administration
• HTRF homogeneous time-resolved fluorescence
• PPI13 triphenylphosphine
• DIAD Diisopropyl azodicarboxylate
• THF tetrahydrofuran
• Me4Si Tetramethylsilane ML
• AUROC Area Under the Receiver Operator Characteristic.
• the present invention generally relates to new compounds for therapeutic uses.
• this disclosure relates to novel compounds with immunomodulatory activities useful for treatment of various cancers.
• compositions of such compounds and methods for treating a cancer patient by administering therapeutically effective amounts of such compound alone, together with other therapeutics, or in a pharmaceutical composition.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.
• the present invention relates to a compound having the formula (I): or a pharmaceutically acceptable salt thereof, wherein
• Ari is an optionally substituted aryl or heteroaryl
• Ri and R2 are, independently, hydrogen, a halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, hetero alkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;
• R3 is halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, hetero alkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted; and Q is: one or several amino acid residues.
• the present invention relates to a compound having the formula (I) as disclosed herein, wherein An is phenyl, 2,3-dihydrobenzo[h][l,4]-dioxine, or phenyl(thiazol-2-yl) methanol.
• the present invention relates to a compound having the formula (I) as disclosed herein, wherein Ri and R 2 are, independently, hydrogen, methyl, hydroxyl, methoxyl, or -OCfkAr.
• the present invention relates to a compound having the formula (I) as disclosed herein, wherein R 3 is CH 3 , CN, or Cl.
• the present invention relates to a compound having the formula (I) as disclosed herein, wherein the compound comprises
• the present invention relates to a compound having a formula (II): or a pharmaceutically acceptable salt thereof, wherein Ri is aryl, substituted aryl, heteroaryl;
• R 2 is a primary or secondary amine containing alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;
• R 3 is halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted; and
• Ari is an aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted.
• the present invention relates to a compound having the formula (II) as disclosed herein, wherein An is phenyl, 2,3-dihydrobenzo[h][l,4]-dioxine, or phenyl(thiazol-2-yl) methanol.
• the present invention relates to a compound having a formula (II) as disclosed herein, wherein R3 is methyl, CN, or a halo.
• the present invention relates to a compound having a formula (II) as disclosed herein, wherein the compound is
• the present invention relates to a compound having a formula (III): or a pharmaceutically acceptable salt thereof, wherein
• Ari is phenyl, 2,3-dihydrobenzo[h][l,4]dioxine, or phenyl(thiazol-2-yl)methanol;
• AT2 is piperidine or pyrrolidine
• X is, independently, a halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, hetero alkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted.
• the present invention relates to a compound having a formula (III) as disclosed herein, wherein X is methyl, cyano, or chloro.
• the present invention relates to a compound having a formula (III) as disclosed herein, wherein the compound is
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.
• the present invention relates to one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is an immune modulator.
• the present invention relates to one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is an inhibitor of PD-1 and PDL-1 signaling pathway.
• the present invention relates to one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is for the treatment of a cancer.
• the present invention relates to a method for treating a patient with a cancer, comprising the step of administering a therapeutically effective amount of one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients, to the patient in need of relief from said cancer.
• the present invention relates to a method for treating a patient with a cancer, comprising the step of administering a therapeutically effective amount of one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients, to the patient in need of relief from said cancer, wherein the compound is an immune modulator.
• the present invention relates to a method for treating a patient with a cancer, comprising the step of administering a therapeutically effective amount of one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, in combination with one or more other compounds of the same or different mode of action, and one or more carriers, diluents, or excipients, to the patient in need of relief from said cancer, wherein the compound is an immune modulator.
• the present invention relates to a method for treating a patient with a cancer, comprising the step of administering a therapeutically effective amount of one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients, to the patient in need of relief from said cancer, wherein said cancer is castration resistant prostate cancer.
• the present invention relates to a method for treating a patient with a cancer, comprising the step of administering a therapeutically effective amount of one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients, to the patient in need of relief from said cancer, wherein the compound is an immune modulator.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, for use as a medicament for cancer.
• the present invention relates to a drug conjugate comprising one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients.
• the present invention relates to a drug conjugate comprising one or more compounds having the formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients, wherein the conjugate confers cell-type or tissue type targeting or the conjugate targets another pathway that synergizes the action of those compounds.
• the present invention relates to a method for treating a cancer patient, comprising the step of administering a therapeutically effective amount of one or more compounds, together with one or more carriers, diluents, or excipients, to a patient in need of relief from said cancer, wherein the compound having the formula of (I), (II), or (III).
• the present invention relates to a compound having a formula (IV): pharmaceutically acceptable salt thereof, wherein
• Ri is hydrogen, a halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;
• R 2 is hydrogen, a halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted; and
• X is a carbon or a nitrogen.
• the present invention relates to a compound having a formula (IV) as disclosed herein, wherein the compound is
• the present invention relates to a compound having a formula (V): pharmaceutically acceptable salt thereof, wherein
• Ri, R 2 , and R 3 independently, represent five substituents selected from the group consisting of hydrogen, a halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, hetero alkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted; or any two adjacent substituents joining together form a cyclic or a heterocyclic moiety.
• the present invention relates to a compound having a formula (V) as disclosed herein, wherein the compounds are
• the present invention relates to a compound having formula VI or VII: or a pharmaceutically acceptable salt thereof, wherein A is a carbon or a nitrogen;
• L is (CH 2 ) n , -SO, -SO2, -CO, -C0(CH 2 )0, where n is 0, 1, 2;
• Ari is an aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;
• Ri is halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, hetero alkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted; and R2 is H, methyl, ethyl or any alkyl;
• R 3 is a halo, -OR, -NO2, cyano, -NR a R b , -N 3 , -S(0) 2 R a , -C(alkyl), -C(cycloalkyl),
• A is a carbon or a nitrogen
• Ri is halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, hetero alkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted; and
• R 2 is independently halo, -OR, -NO 2 , cyano, -NR a R b , -N 3 , -S(0) 2 R a , -C(alkyl), -
• R 4 is independently halo, -OR, -N02, cyano, -NR a R b , -N 3 , -S(0) 2 R a , -C(alkyl), -
• the present invention relates to a compound having formula IX: or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2;
• Ri is halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, hetero alkenyl, hetero alkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted; and R 2 is independently halo, -OR, -NO 2 , cyano, -NR a R b , -N 3 , -S(0) 2 R a , -C(alkyl), - C(cycloalkyl), C(alkynyl), C
• R 4 is independently halo, -OR, -NO 2 , cyano, -NR a R b , -N 3 , -S(0) 2 R a , -C(alkyl), - C(cycloalkyl), C(alkynyl), C(haloalkyl), acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted, wherein R, R a , and R b are independently an alkyl; and
• Ari is an aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is an immune modulator.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is an inhibitor of PD-1 and PDL-1 signaling pathway.
• the present invention relates to a method for treating a cancer patient comprising the step of administering a therapeutically effective amount of one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers, wherein the compound is an inhibitor of PD-1 and PDL-1 signaling pathway.
• the present invention relates to a method for treating a cancer patient comprising the step of administering a therapeutically effective amount of one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, and one or more carriers, diluents, or excipients, to the cancer patient in need of relief from said cancer.
• the present invention relates to a method for treating a cancer patient comprising the step of administering a therapeutically effective amount of one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein in combination with one or more other compounds of the same or different mode of action, and one or more carriers, diluents, or excipients, to the cancer patient in need of relief from said cancer.
• the present invention relates to a method for treating a cancer patient comprising the step of administering a therapeutically effective amount of one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, and one or more carriers, diluents, or excipients, to the cancer patient in need of relief from said cancer, wherein the compound is an inhibitor of PD- 1 and PDL- 1 signaling pathway.
• the present invention relates to a method for treating a cancer patient comprising the step of administering a therapeutically effective amount of one or more compounds having the formulae of (IV) ⁇ (IX) as disclosed herein, and one or more carriers, diluents, or excipients, to the cancer patient in need of relief from said cancer, wherein said cancer is castration resistant prostate cancer.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds having the formulae of (I) ⁇ (IX) as disclosed herein, and one or more carriers, diluents, or excipients, for use as a medicament for cancer.
• the Programmed Cell Death Protein 1/Programmed Death- Ligand 1 (PD-l/PD- Ll) interaction is an immune checkpoint utilized by cancer cells to enhance immune suppression.
• PD-l/PD- Ll The Programmed Cell Death Protein 1/Programmed Death- Ligand 1
• synthesizing and validating large libraries of small- molecules to inhibit PD-1/PD-L1 interaction in a blind manner is both time-consuming and expensive.
• Our model incorporates two features: docking scores to represent the energy of binding (E) as a global feature and subgraph features through a graph neural network (GNN) of molecular topology to represent local features.
• This Energy-Graph Neural Network (EGNN) model outperforms traditional machine learning methods as well as a simple GNN with a FI score of 0.9524 and Cohen’s kappa score of 0.8861 for the hold out test set, suggesting that the topology of the small molecule, the structural interaction in the binding pocket, and chemical diversity of the training data are all important considerations for enhancing model performance.
• a Bootstrapped EGNN model was used to select compounds for synthesis and experimental validation with predicted high and low potency to inhibit PD-1/PD-L1 interaction.
• the potent inhibitor (4-((3-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2,6- dimethoxybenzyl)-D-serine, is a hybrid of two known bioactive scaffolds, and has an IC50 values of 339.9 nM that is comparatively better than the known bioactive compound.
• our bootstrapped EGNN model will be useful to identify target- specific high potency molecules designed by scaffold hopping, a well-known medicinal chemistry technique.
• Random Forest (RF) 17 l9 Graph Convolution Network 20 , and Graph Neural Networks (GNN) 21,22 have been used for drug design and predicting drug-target interactions 23,24 .
• new architectures utilizing a combination of graph features in the binding site of a protein have shown great promise for calculating binding affinities and determining whether a compound will bind to a target. 20,22
• FIG. 2A shows the distribution of low and high potency molecules and general scaffolds in the BMS and Incyte patents.
• the BMS patents have 372 high potency compounds and 302 low potency compounds while the Incyte patents have 47 high potency compounds and 41 low potency compounds respectively.
• the BMS patent scaffolds contains 417 derivatives of (2-methyl-3-biphenylyl)methanol and 257 derivatives of [3-(2,3-dihydro-l,4-benzodioxin-6-yl)-2-methylphenyl]methanol shown in Figure 2A (bottom - left) with R groups as CN, Cl, Br, and CH3.
• Incyte patent scaffolds have distinct sub-scaffolds, denoted as A and B in Figure 2A (bottom - right).
• X denotes for either N or C — R groups (R: Alkyl groups).
• a PD-L1 homodimer crystal structure (PDB ID: 5N2F) was selected for docking all the compounds in this manuscript.
• a PD-1/PD-L1 crystal structure (PDB ID: 4ZQK) was also used to check whether the binding site location of PD-L1 in the homodimer crystal structure (5N2F) overlapped and aligned with each other using the PyMol software package 40 (Fig. 3A). In Fig.
• the selected binding site of the PD-L1 homodimer on the overlapped and aligned crystal structures is shown to indicate that the formation of the homodimer of PD-L1 with small molecules blocks the PD-1/PD-L1 interaction.
• a known inhibitor of the PD-1/PD-L1 interaction (ligand ID: 8HW) 8 in the selected binding site (Fig. 3C) suggests that the selected binding site corresponding to PD-L1 homodimers is relevant to develop PD-1/PD-L1 inhibitors. Therefore, the docking interactions of the PD-L1 homodimer will be relevant towards identifying PD-1/PD-L1 inhibitors.
• CANDOCK 31 was used to generate docking conformations of small molecules with PD-L1 homodimer (see Experimental Section on Generation of Energy Features with Docking and Energy Vector (E) in EGNN for details). Before developing a machine learning method, we also assessed the ability of only using the docking scores for compounds in the training set for each of the 96 potential energy scoring functions 31 in CANDOCK to classify the high potency vs low potency molecules. Cohen’s Kappa scores were used to select the best scoring functions to differentiate between two classes. (Table SI). The scoring function, radial cumulative complete 15 (RCC15) acquired the highest Cohen’s kappa score of 0.41447.
• FIG. 1 shows that the EGNN model is a combination of local features of the small molecule represented as a GNN (see Graph Neural Network for Molecular Graphs in EGNN) along with global features of protein-ligand interaction represented as docking scores (see section Generation of Energy Features with Docking and Energy Vector (E) in EGNN).
• the EGNN was trained with 88 small molecules with high and low potency for PD-1/PD-L1 inhibition extracted from two Incyte patents (see Patent Data for Training the EGNN Model).
• the EGNN and GNN models were trained with different training sets to examine the effect of chemical diversity on model performance for classification of high and low potency molecules.
• Two datasets (BMS and Incyte) were used separately and in combination to train the EGNN model and determine the best dataset to predict PD-1/PD-L1 inhibitors.
• Splitting of the dataset into training-validation set and test set (4:1) were carried out using two different methods: (1) using a random splitter on shuffled data and (2) using a scaffold splitting method by DeepChem library. 43 Then training was carried out with fivefold cross validation and test sets were used to evaluate the models’ prediction ability.
• Figure 4A shows how data sets were split within the train- validation-test set scheme. Initial dataset was split into two sets with the 4:1 ratio based on the scaffold splitting or random shuffled splitting. Then the 80% dataset was used as the training and validation dataset while the 20% dataset was used as the hold out test set to evaluate model performances.
• Fig. 4A shows average FI scores (over five-fold cross-validation) for both models trained with BMS compounds, Incyte compounds, and the union of these sets.
• the average FI scores of the EGNN and GNN models trained with Incyte data were 0.956 ( ⁇ 0.051) and 0.678 ( ⁇ 0.157), respectively (Fig. 4A). This result suggests that the EGNN trained model with Incyte data that contains diverse chemical scaffolds (Fig. 2C) performs much better than the GNN trained with the same data set.
• the average FI score is comparable for both models with 0.992 ( ⁇ 0.007) for the EGNN model and 0.948 ( ⁇ 0.022) for the GNN model. This suggests that the GNN model performs well with smaller chemical diversity in the training data as compared to larger chemical diversity in training data. However, the EGNN model performs well with both datasets, indicating that it is a superior model to the GNN.
• Obtained AUROC, AUPRC, Precision, Recall, FI Score and Cohen’s kappa values are tabulated in the Table 1 for all four models.
• the SVM model was trained using the ‘svm’ package in scikit-learn library 46 with the "linear” kernel and the RF was trained using the ‘RandomForestClassifier’ in scikit-learn library 46 with 500 trees.
• the ‘metrics’ module in scikit-learn package 46 was used for statistics AUROC, precision, recall, FI score and Cohen’s kappa. Precision-recall curves for models and AUPRC values were obtained using the ‘precrec’ library 47 in R programming language.
• the EGNN model outperforms all the other models with values of 0.9250, 0.9212, 0.9091, 1.0000, 0.9524, and 0.8861 for AUROC, AUPRC, precision, recall, FI score, and Cohen’s kappa respectively (Table 1). Comparing precision-recall curves of these four models ( Figure 4E) also confirmed that the EGNN model outperforms all three other models. Taken together, the combined local and global features in EGNN gives the best performance with the Incyte dataset.
• Table 1 AUROC, AUPRC, Precision, Recall, FI Score and Cohen’s kappa of the EGNN for PD-1/PD-L1 inhibitor predictions compared to other baseline models, such as, Random Forest, SVM, and GNN models. All models were trained on the Incyte dataset and evaluated based on the same hold out test set.
• Bootstrapping is an essential statistical technique that can be used to select confident molecules for synthesis and experimental validation based on agreements among multiple models.
• the bootstrapped EGNN model identified high and low potency small molecules as PD-1/PD-L1 inhibitors that were synthesized and then experimentally verified with HTRF binding assay (see Table 2 for summary). Specifically, we selected 4 molecules predicted to be high or low potent for PD-1/PD-L1 inhibition for testing based on bootstrapped EGNN SoftMax average scores and standard deviation (see EGNN SoftMax scores in Table 2).
• the predicted high potency molecule (compound 4b) is (4-((3-(2,3-dihydrobenzo[h][l,4]dioxin-6-yl)-2- methylbenzyl)oxy)-2,6-dimethoxybenzyl)-D-serine, a hybrid of two BMS molecules, 4a (BMS-1) and BMS-1002 containing (2-methyl-3-biphenylyl)methanol and [3-(2,3-dihydro-
• reaction conditions (i) BH3*THF complex (1.0 M in THF), Anhydrous THF, 0 °C to rt, 2 days; (ii) PPI13, DIAD, 0 °C to rt, 20 h, anhydrous THF; (iii) amine component, NaBHiCN, cat. AcOH, DMF, 80 °C or room temperature, lh or 3 h or overnight.
• the HTRF assay confirmed that compound 4b has an IC50 of 339.9 nM (see Experimental Section for details) to inhibit PD-1/PD-L1 interaction (Figure 5D). This is comparatively better than the IC50 of 521.5 nM for the BMS compound 4a that was synthesized and tested in our lab (BMS-1 molecule in the BMS patent WO 2015/034820 Al). It should be noted that the BMS-1 molecule was denoted with the IC50 of 6-100 nM with HTRF assay in the BMS patent 7 .
• the model recognized it as a low potency molecule and the actual test showed that it is a poor inhibitor for PD1/PD-L1 with an IC50 of 1261 nM.
• it’s pairwise Tanimoto similarity score with the control compound (4a) is only 0.5074.
• Cancer immunotherapy marks a major step in treating cancer and the development of PD-1/PD-L1 immune checkpoint inhibitors have been an important area of research for treatment of several tumors.
• PD-1 pembrolizumab, nivolumab, and cemiplimab
• PD-L1 atezolizumab, durvalumab, and avelumab
• U.S. FDA U.S. FDA
• new small molecules PD-1/PD-L1 inhibitors have been developed 43 along with structure determination of human PD-1/PD-L1 complex and cocrystals of inhibitory ligands 44 ⁇ 46 .
• Still the field is very active in search for new small molecules to inhibit this important checkpoint and we hope to enhance the speed of this search with the use of new structure-based ML methods that have been benchmarked extensively and tested prospectively.
• EGNN based on combining local features of the small molecule topology and global features of the small molecule interacting within the binding pocket as energetic scores to select, synthesize and experimentally validate potent inhibitors of PD-1/PD-L1 interaction.
• EGNN outperforms traditional ML architectures, such as, RF, SYM that include both local and global features, as well as the GNN model that uses only local features of small molecular topology.
• the predicted high potency molecule (4-((3-(2,3-dihydrobenzo[h][l,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2,6- dimethoxybenzyl)-D-serine, is a hybrid of two BMS high potency molecular scaffolds, and has an IC50 value of 339.9 nM for inhibiting PD-1/PD-L1 interaction, suggesting the ability of EGNN model to do scaffold hopping to identify new inhibitors. Accurate selection of low potency molecules with different scaffolds suggests practical utility of our bootstrapped model for selection of compounds for synthesis, a hard problem in the field of ML based drug design.
• Our EGNN methodology can be further developed with the addition of more chemically diverse data, and incorporating reinforcement iterative learning with experiments performed in each step for developing a library of structurally diverse small molecule inhibiting PD-1/PD-L1 interaction to guide structure- activity relationships.
• this approach can be adapted to identify small molecule immunomodulators by targeting other immune checkpoints, as well as, generally used to include local and global features for target-based drug design.
• a multiplication factor of 10000 factor was used to not deal with decimal values that improves data accuracy during calculation.
• the AR ratio indicating “specific signal” of the compound disrupting the PD-1/PD-L1 interaction was calculated by subtracting background HTRF ratio (negative DMSO control in our work) from each compound (sample) HTRF ratio as follows;
• the IC50 value for PD-1/PD-L1 inhibition was determined by analyzing the log of the concentration-response curves to fit a sigmoid curve with four-parameter logistic (4PL) regression using the GraphPad Prism Software version 8.3.0 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com.
• the HTRF_IC50_Data.xlsx data file with all replicates is provided as a Supporting File for use in GraphPad Prism Software to calculate IC50 values.
• the EGNN model was developed using PyTorch 47 . All scripts for implementing the machine learning model and results are provided on GitHub at https://github.com/chopralab/egnn.
• the Fig. 1 shows the overview of the EGNN machine learning architecture.
• the following sections include details of the EGNN architecture.
• M e indicate matrices
• Italicized non-bold letters e.g. S, G, v, and e
• the GNN converts a molecular graph into a low dimensional real valued vector y e with two neural network-based functions; transition and output. 21
• each vertex ( v ) is updated with considering the information of its neighboring vertices and edges by the transition function. These vertices have been mapped into a real valued vector y e by the output function. Both functions are differentiable. All the input features and weights of the GNN model are updated using back propagation with the help of the cross-entropy loss function.
• V and E are sets of vertices and edges respectively.
• atoms can be defined as vertices and chemical bonds can be defined as edges.
• all the atoms and chemical bonds will be embedded as real valued vectors with d-dimensions based on their different types. Since the diversity of atoms (eg: C, N, O, etc.) and bonds (eg: single bonds, double bonds, triple bonds, etc.) in a small molecule is limited, the number of learning parameters are limited. Therefore, a strategy called r-radius sub-graphs 50 was used to avoid this limitation.
• N(i, r) ⁇ £ ⁇ , which is the set of all atoms in the molecule.
• the r-radius sub-graph for the edge between ith and yth atoms was defined as follows; [00152] Randomly initialized embeddings (Fig. 1) are assigned to each r-radius edge and vertex (v ⁇ r)' ) based on the type. Backpropagation has been used to train these random embeddings.
• e M d is the embedded vector for the i th vertex of a given molecular graph G at time step t.
• W neighbor e M. dx2d and b neighbor E M. dx2d are the weight matrix and the bias vector respectively.
• the vector between the ith and j th atoms (vertices) of the molecular graph after the time step t is defined as e[y ⁇
• edge transition function is used to update each embedded edge vector ej ⁇ during the training process.
• W ed5e E R dxd , b edge E M dxl are the weight matrix and the bias vector respectively.
• W ed5e E R dxd , b edge E M dxl are the weight matrix and the bias vector respectively.
• W ed5e E R dxd , b edge E M dxl are the weight matrix and the bias vector respectively.
• W ed5e E R dxd are the weight matrix and the bias vector respectively.
• b edge E M dxl are the weight matrix and the bias vector respectively.
• the transition function generates an updated set of atom (vertex) vectors Then the output function uses this set of atom vectors to obtain an unique molecular vector y molecule (Fig. 1A), which is defined as follows; wherein, the total number of vertices in the full molecular graph is denoted by the
• S ⁇ j is the normalized docking energy value for the energy score with ith potential energy function for the yth docked molecule.
• Si j is the docking energy score before normalization.
• max(S j ) and min(S j ) are the maximum and minimum energy values within the yth scoring function for all docked molecules.
• Cohen’s Kappa scores were calculated for each scoring function for all the training set data using Cohen_kappa_score tool in scikit-learn package 46 . All the scoring functions which gave a positive Cohen’s kappa score were selected and top in each class was selected for the EGNN model.
• the normalized docking score vector for each molecule in the EGNN model is represented using RCR15 and RCC15 normalized potential energy scoring functions as y ener gy G D3 ⁇ 4 2 ( Figure IB).
• the normalized docking energy score vector (y energy) is concatenated with the molecular vector output of the GNN (y molecule) ⁇
• the concatenated long vector (y molecule Q was used for the training as follows to obtain an output vector x ou tput e D3 ⁇ 4 2 ; wherein ® denotes concatenation, YY output e R 2x(d+96) denotes the weight matrix and the b output e D3 ⁇ 4 2 denotes the bias vector.
• the p t is the probability of the given y t .
• the EGNN model was trained with back propagation with given SMILES strings, the vectors of RCR15 and RCC15 scores generated by CANDOCK 31 and their high potency or low potency status with the PD-L1 protein.
• the trained model can be used to predict the probability of a given molecule to be a high or low potent molecule towards the PD-L1 protein.
• BMS compound 4a (BMS-1 or KPGC01S94) 7 as well as compounds 4b-c were synthesized according to the reported procedures starting from compound 1, 2a-b, 3a-b and spectral data were in accordance with reported data. 6-8
• Step-1 2-(3-bromo-2-methylphenyl)-5-((4-fluorophenyl) (piperidin-l-yl)methyl)-
• Step-2 2-((4-fluorophenyl)(piperidin-l-yl)methyl)-5-(2-methyl-[l,r-biphenyl]-3- yl)-l,3,4-oxadiazole (2a): In a clean dried screw cap vial with magnetic stir bar, a mixture of 2-(3-bromo-2-methylphenyl)-5-((4-fluorophenyl) (piperidin-l-yl)methyl)-l,3,4-oxadiazole (1 equiv), phenylboronic acid (2 equiv) and PdChidppfh-CHiCh (3 mol%) were taken and purged once with Argon.
• Step-1 3-Bromo-/V,2-dimethylaniline (1 equiv), (2,3-dihydrobcnzo[/?][ 1 ,4Jdioxin- 6-yl)boronic acid (1.5 equiv), PdChidppO ⁇ CFTCh (3 mol%) in Toluene:Ethanol (1.5:0.5 mL) and purged twice with Argon. 1M NaHCCL (1.5 mL) was added under inert atmosphere and it was allowed to stir at 80 °C for 45 mins. The reaction was monitored by TLC. The product was purified by flash column chromatography using 0-60% Hexane: Ethylacetate to get oily product (77% yield).
• Step-2 A mixture of 3-(2,3-dihydrobenzo[h][l,4]dioxin-6-yl)-/V,2- dimethylaniline (1 equiv), propionaldehyde (1.1 equiv), (N-
• Step-1 3-Bromo-/V,2-dimethylaniline (1 equiv), phenylboronic acid (1.5 equiv),
• Step-2 A mixture of N,2-dimethyl-[l,r-biphenyl]-3-amine (1 equiv), propionaldehyde (1.1 equiv), (N-Isocyanoimino)triphenylphosphorane in DCM was added benzoic acid (1.1 equiv) in portions. The reaction mixture was stirred at 40 °C for 2-3 hours. The reaction was monitored by TLC. The product was purified by flash column chromatography using 0-60% Hexane: Ethylacetate to get oily product (48% yield). [00202]

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=77671929

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (1)

Citations (3)

Family Cites Families (4)

• 2021
  • 2021-03-05 WO PCT/US2021/020992 patent/WO2021183370A1/en not_active Ceased
  • 2021-03-05 CN CN202180033571.3A patent/CN115551497B/zh active Active
  • 2021-03-05 EP EP21767165.0A patent/EP4117647A4/en active Pending
  • 2021-03-05 JP JP2022554529A patent/JP7796032B2/ja active Active
  • 2021-03-05 CA CA3175848A patent/CA3175848A1/en active Pending
  • 2021-03-05 US US17/908,530 patent/US12448359B2/en active Active
  • 2021-03-05 MX MX2022011171A patent/MX2022011171A/es unknown
• 2025
  • 2025-12-22 JP JP2025272737A patent/JP2026040565A/ja active Pending

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events